Trinity Bio ADR (TRIB) 13.02 $TRIB
ERBA Diagnostics, Inc. Announces Extension of CEO'S Contract Term and Appointment of Hayden Jeffreys to Board of Directors
GlobeNewswire - Tue May 31, 3:15PM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company"
, a fully integrated in vitro diagnostics company, announced today that it has entered into an amendment to employment agreement with Mohan Gopalkrishnan, the Company's Chief Executive Officer, which extended Mr. Mohan's term of employment for seven (7) months, such that his contract term will now expire on December 31, 2016.
TRIB: 13.02 (+0.19), ERB: 0.53 (-0.02)
Trinity Biotech Announces Results for Q1, 2016
GlobeNewswire - Tue Apr 19, 7:29AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2016.
TRIB: 13.02 (+0.19)
Trinity Biotech plc to Announce First Quarter Fiscal Year 2016 Financial Results
GlobeNewswire - Fri Apr 15, 5:56AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2016 on Tuesday, April 19, 2016. The Company has scheduled a conference call for that same day, Tuesday, April 19, 2016 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
TRIB: 13.02 (+0.19)
43.3% Return Seen to Date on SmarTrend Trinity Biotech Call (TRIB)
Comtex SmarTrend(R) - Wed Feb 10, 4:43PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 7 months, Trinity Biotech has returned 43.30% as of today's recent price of $9.67.
TRIB: 13.02 (+0.19)
Shares of TRIB Down 38.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 03, 10:09AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 38.38% as of today's recent price of $10.51.
TRIB: 13.02 (+0.19)
36.0% Return Seen to Date on SmarTrend Trinity Biotech Call (TRIB)
Comtex SmarTrend(R) - Tue Jan 26, 5:49PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 35.97% as of today's recent price of $10.92.
TRIB: 13.02 (+0.19)
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 45.07 (+0.32), MYGN: 31.34 (+0.36), VIVO: 19.48 (+0.12), A: 47.76 (-0.35), DHR: 81.31 (-0.13), ABAX: 49.48 (+0.02), DGX: 86.42 (+0.06), TRIB: 13.02 (+0.19), HOLX: 38.96 (+0.47)
US Infectious Disease Testing Market Growth of 5.81% by 2019 - Analysis, Technologies & Forecasts Reports 2015-2019 - Key Vendors: Roche, Bio-Rad Laboratories & Trinity Biotech - Research and Markets
BusinessWire - Thu Jan 21, 7:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/t5fwx3/infectious) has announced the addition of the "Infectious Disease Testing Market in the US 2015-2019" report to their offering.
TRIB: 13.02 (+0.19)
US Infectious Disease Testing Market Growth of 5.81% by 2019 - Analysis, Technologies & Forecasts Reports 2015-2019 - Key Vendors: Roche, Bio-Rad Laboratories & Trinity Biotech
M2 - Thu Jan 21, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqsrqq/infectious) has announced the addition of the "Infectious Disease Testing Market in the US 2015-2019" report to their offering. This market report forecasts the infectious disease testing market in the US to grow at a CAGR of 5.81% over the period 2014-2019. The report covers the current scenario and the growth prospects of the infectious disease testing market in the US for the period of 2015-2019. To calculate the market size, we consider the revenue generated from the sales of equipment and consumables from molecular diagnostics, POCT diagnostic devices, and immunodiagnostics, which are used to detect infectious diseases: Questions Answered: - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned: - Abbott Diagnostics - Alere - Beckman Coulter Diagnostics - Roche - Siemens Healthcare - Abaxis - Acon Laboratories - Avioq - BD - Bio-Rad Laboratories - Cavidi - Cepheid - Chembio Diagnostic Systems - Clarity Diagnostics - EMD Millipore - Epitope Diagnostic - Gold Standard Diagnostics - Hologic - Immunetics - InBios International - Life Technologies - Maxim Biomedical - Mindray - OraSure Technologies - Ortho Clinical Diagnostics - Quidel Corporation - Thermo Fisher Scientific - Trinity Biotech Report Structure: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Market landscape PART 06: Market segmentation by application PART 07: Geographical segmentation PART 08: Market drivers PART 09: Impact of drivers PART 10: Market challenges PART 11: Impact of drivers and challenges PART 12: Market trends PART 13: Vendor landscape PART 14: Key vendor analysis PART 15: Key recommendations for vendors/investors PART 16: Appendix For more information visit http://www.researchandmarkets.com/research/fqsrqq/infectious
LIFE: 3.37 (-0.04), ABAX: 49.48 (+0.02), CPHD: 35.97 (+0.64), TRIB: 13.02 (+0.19), HOLX: 38.96 (+0.47), OSUR: 6.76 (-0.06)
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
GlobeNewswire - Wed Jan 20, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Company's Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this capacity, through an expansion of Dr. Burger's existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune diseases and cancer. He recently initiated the Company's evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Company's Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
APTO: 2.52 (+0.02), TRIB: 13.02 (+0.19), OSUR: 6.76 (-0.06)
Trinity Biotech Shares Down 37.0% Since SmarTrend's Sell Call (TRIB)
Comtex SmarTrend(R) - Tue Jan 19, 5:04PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 36.97% as of today's recent price of $10.75.
TRIB: 13.02 (+0.19)
Global Point of Care (POC) Pregnancy and Fertility Testing Market Report 2015
M2 - Tue Jan 19, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/d22vw2/poc_pregnancy_and) has announced the addition of the "POC Pregnancy and Fertility Testing Market" report to their offering. The female reproductive system is complex both in structure and in function. From birth to senescence, the organs of the female reproductive system function in concert with each other, with the brain, and with other endocrine organs. This integrated functioning constitutes some of the most intricate and elegant processes of the human body. Because the functioning of the female reproductive system has an enormous impact on the life of the individual women, increasing importance is placed on the active involvement of women in understanding their own health care needs such as determination of pregnancy and fertility. Point of care (POC) testing, diagnostic tests performed at or near the site where a patient is located, may be performed by laboratory personnel but are often performed by non-laboratory personnel, including patients themselves (self-testing). The menu for POC testing includes pregnancy and fertility testing. Point of Care (POC) Pregnancy and Fertility Testing Market examines the testing market for these segments, including: - 2014 Pregnancy and Fertility CLIA Waivers - Global POC Pregnancy and Fertility Testing Market Analysis, 2012-2019 - POC Pregnancy and Fertility Self-Testing Market Analysis, 2014 and 2019 - POC Pregnancy and Fertility Professional Testing Market Analysis, 2014 and 2019 - Global POC Pregnancy and Fertility Testing Market Revenues and Market Share of Leading Suppliers, 2014 The professional sector is made up of tests used in hospitals, physician offices and clinics. The over-the-counter (OTC) sector for pregnancy and ovulation (LH) includes tests available in pharmacies and other retail establishments. Both market segments are expected to grow over the report's forecast period. Many companies are involved in the development and/or marketing of POC pregnancy and fertility testing products. Among the top and/or innovative competitors discussed within the Corporate Profiles are firms that maintain leading positions in the market such as: - Alere - Church & Dwight - Insight Pharmaceuticals - Meridian - Quidel Key Topics Covered: ONE: EXECUTIVE SUMMARY - Overview of POC Testing - Pregnancy and Fertility - Size of the Market - POC Professional Testing - POC Pregnancy and Fertility Self-Testing - Growth of the Market - Leading Competitors TWO: POC PREGNANCY AND FERTILITY TESTING - Products - Market Size and Growth - POC Pregnancy and Fertility Self-Testing - POC Pregnancy and Fertility Professional Testing - Competitive Analysis - Product Innovation THREE: CORPORATE PROFILES - Alere Inc - Ani Biotech Oy - Beckman Coulter, Inc - bioMerieux SA - Cen-Med Enterprises, Inc. - Church & Dwight Co., Inc - EKF Diagnostics GmbH - EKLA Corporation - Insight Pharmaceuticals LLC - Meridian BioScience, Inc - Opko Health, Inc - Polymed Therapeutics Inc. - Polymedco, Inc - Quidel Corporation - Radiometer Medical ApS - Ramco Laboratories, Inc. - Roche Diagnostics Corporation - Siemens Healthcare - Stanbio Laboratory - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/d2...gnancy_and
CHD: 98.35 (+0.11), VIVO: 19.48 (+0.12), OPK: 9.95 (unch), TRIB: 13.02 (+0.19), ALR: 37.21 (-0.29)
Hemoglobin A1c Testing Markets 2016 - The Global Prevalence of Diabetes Mellitus Continues to Increase Rapidly, with More than 366 Million Diabetics Worldwide
M2 - Wed Jan 13, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/wqvpk6/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Markets" report to their offering. Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase rapidly, with more than 366 million diabetics worldwide, hemoglobin A1c testing is now an essential assay in the diabetes testing repertoire. Its clinical utility and improvements in its accuracy and implementation of standardized protocols have translated into continued market growth. This report describes the specific market segment that encompasses hemoglobin A1c testing for diagnosing and monitoring diabetes. The study reviews all of the generally accepted clinical analytical methods that are currently in use today for measuring HbA1c levels. Moreover, it examines clinical measurement devices and reagents as utilized in hospitals, clinics, doctor's offices and at-home care locations. The report also analyzes almost all of the companies known to be marketing, manufacturing or developing hemoglobin A1c testing. Detailed tables and charts with sales forecasts and market-share data are also included. Companies Mentioned - Abbott Laboratories - A. Menarini Diagnostics - Alere, Inc. - ARKRAY USA, Inc. - Axis-Shield Plc - Bayer Healthcare Diagnostics - Beckman Coulter, Inc - Bio-Rad Laboratories, Inc. - EKF Diagnostics - Infopia Co., Ltd. - Ortho Clinical Diagnostics (part of Johnson & Johnson) - Quotient Diagnostics - Randox Laboratories - Roche Diagnostics - Siemens AG - Tosoh Bioscience, Inc. - Trinity Biotech Plc Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Overview of HbA1c Testing 5. HbA1c Testing Devices on the Market 6. Business Trends in HbA1c Testing 7. Regulatory Environment and Insurance Reimbursements 8. Company Profiles For more information visit http://www.researchandmarkets.com/research/wq...globin_a1c
JNJ: 125.15 (-0.08), ABT: 45.07 (+0.32), TRIB: 13.02 (+0.19), ALR: 37.21 (-0.29)
Trinity Biotech Has Returned 36.8% Since SmarTrend Recommendation (TRIB)
Comtex SmarTrend(R) - Tue Jan 12, 11:03AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 36.79% as of today's recent price of $10.78.
TRIB: 13.02 (+0.19)
Downtrend Call Working As Trinity Biotech Stock Falls 31.1% (TRIB)
Comtex SmarTrend(R) - Tue Jan 05, 9:15AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 5 months, Trinity Biotech has returned 31.11% as of today's recent price of $11.75.
TRIB: 13.02 (+0.19)
Dengue Virus Pipeline Review, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/43hcsk/dengue_virus) has announced the addition of the "Dengue Virus - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dengue Virus diagnostic tests pipeline products. Key Topics Covered: - Extensive coverage of the Dengue Virus diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Dengue Virus diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Dengue Virus diagnostic tests under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Companies Mentioned: - Acobiom - Ceres Nanosciences, Inc. - Chembio Diagnostic Systems, Inc. - Corgenix Medical Corporation - Epistem Holdings Plc - FK-Biotecnologia SA - GeneFirst Ltd - InBios International, Inc. - Innova Biotechnology Co., Ltd. - InstantLabs Medical Diagnostics Corporation - Institut Pasteur - Malaysian Bio-Diagnostics Research Sdn Bhd - McGill University - Micronics, Inc. (of Sony Group) - Nanyang Technological University - National University of Singapore - Trinity Biotech Plc - Universitas Padjadjaran - University of California, Berkeley - University of Texas Medical Branch at Galveston - Vircell S.L - Whidiag SAS Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Dengue Virus - Pipeline Products under Development by Companies 5 Dengue Virus Companies and Product Overview 6 Dengue Virus- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/43...ngue_virus
TRIB: 13.02 (+0.19)
Trinity Biotech Down 28.9% Since SmarTrend Downtrend Call (TRIB)
Comtex SmarTrend(R) - Mon Dec 21, 3:58PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 5 months, Trinity Biotech has returned 28.94% as of today's recent price of $12.12.
TRIB: 13.02 (+0.19)
Global In Vitro Diagnostic Instrumentation & Strategic Profiles of Leading Suppliers - Analysis, Technologies & Forecasts 2016
M2 - Mon Dec 21, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/8znjj3/2016_world_in) has announced the addition of the "2016 World In Vitro Diagnostic Instrumentation and Strategic Profiles of Leading Suppliers" report to their offering. This new report reviews operating characteristics and features of major automated and semi-automated high-, medium-, and low-volume/POC in vitro diagnostic systems within the following market segments: - Blood Typing, Grouping, and Screening - Cancer Diagnostics - Clinical Chemistry and Immunodiagnostics - Coagulation Testing - Hematology and Flow Cytometry - Microbiology - Molecular Diagnostics The report also presents strategic assessments of current and emerging suppliers of in vitro diagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. The companies analyzed in the report include: - Abbott - Affymetrix - Agilent Technologies - Alere/AdnaGen - Applied Gene Technologies - Lonza - Mackay Life Sciences - Matritech/Alere - Monogram Biosciences/LabCorp - Shimadzu - Siemens - Sienco - Sierra Molecular - Sysmex - Takara Bio - Targeted Diagnostics & Therapeutics - Tecan Group - Thermo Fisher - Tosoh - Trinity Biotech - Veridex - Vermillion - Wako - Wallac/PE - Zycare/Alere - Zyla Contains 370 pages For more information visit http://www.researchandmarkets.com/research/8z...6_world_in
A: 47.76 (-0.35), TRIB: 13.02 (+0.19)
ERBA Diagnostics, Inc. Announces Extension of CEO'S Contract Term and Appointment of Hayden Jeffreys to Board of Directors
GlobeNewswire - Tue May 31, 3:15PM CDT
ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the "Company"
, a fully integrated in vitro diagnostics company, announced today that it has entered into an amendment to employment agreement with Mohan Gopalkrishnan, the Company's Chief Executive Officer, which extended Mr. Mohan's term of employment for seven (7) months, such that his contract term will now expire on December 31, 2016. TRIB: 13.02 (+0.19), ERB: 0.53 (-0.02)
Trinity Biotech Announces Results for Q1, 2016
GlobeNewswire - Tue Apr 19, 7:29AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2016.
TRIB: 13.02 (+0.19)
Trinity Biotech plc to Announce First Quarter Fiscal Year 2016 Financial Results
GlobeNewswire - Fri Apr 15, 5:56AM CDT
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2016 on Tuesday, April 19, 2016. The Company has scheduled a conference call for that same day, Tuesday, April 19, 2016 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
TRIB: 13.02 (+0.19)
43.3% Return Seen to Date on SmarTrend Trinity Biotech Call (TRIB)
Comtex SmarTrend(R) - Wed Feb 10, 4:43PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 7 months, Trinity Biotech has returned 43.30% as of today's recent price of $9.67.
TRIB: 13.02 (+0.19)
Shares of TRIB Down 38.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 03, 10:09AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 38.38% as of today's recent price of $10.51.
TRIB: 13.02 (+0.19)
36.0% Return Seen to Date on SmarTrend Trinity Biotech Call (TRIB)
Comtex SmarTrend(R) - Tue Jan 26, 5:49PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 35.97% as of today's recent price of $10.92.
TRIB: 13.02 (+0.19)
High-Growth Diagnostic Testing Markets Report - 2016 Edition
M2 - Fri Jan 22, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzwf2g/highgrowth) has announced the addition of the "High-Growth Diagnostic Testing Markets" report to their offering. There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned - A Menarini Diagnostics - Abaxis, Inc - Abbott Laboratories - Accurex Biomedical Pvt Ltd - Adeza Biomedical Corporation (Hologic) - Agilent Technologies, Inc - American Bio Medica Corporation - Ani Biotech Oy Ltd - Applied Spectral Imaging - Avitar, Inc - Axis-Shield Plc - Bayer Corporation - Beckman Coulter (now part of Danaher) - Becton, Dickinson and Company - Bio-Rad Laboratories, Inc - Biomerica, Inc - Enterix, Inc (Subsidiary of Quest Diagnostics) - Genetix (Molecular Devices) - Genzyme Diagnostics - Hologic Gen Probe - LifeScan - Matritech - Medix Biochemica - Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc) - Meridian Bioscience - Myriad Genetics, Inc - NOVA Biomedical - OraSure - Roche Diagnostics - Shanghai SIIC Kehua Biotech Co, Ltd (Kehua Biotech) - Shionogi & Co, Ltd - Siemens Healthcare Diagnostics - Spectral Diagnostics, Inc - Trinity Biotech Plc - V?samed, Inc For more information visit http://www.researchandmarkets.com/research/gzwf2g/highgrowth
ABT: 45.07 (+0.32), MYGN: 31.34 (+0.36), VIVO: 19.48 (+0.12), A: 47.76 (-0.35), DHR: 81.31 (-0.13), ABAX: 49.48 (+0.02), DGX: 86.42 (+0.06), TRIB: 13.02 (+0.19), HOLX: 38.96 (+0.47)
US Infectious Disease Testing Market Growth of 5.81% by 2019 - Analysis, Technologies & Forecasts Reports 2015-2019 - Key Vendors: Roche, Bio-Rad Laboratories & Trinity Biotech - Research and Markets
BusinessWire - Thu Jan 21, 7:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/t5fwx3/infectious) has announced the addition of the "Infectious Disease Testing Market in the US 2015-2019" report to their offering.
TRIB: 13.02 (+0.19)
US Infectious Disease Testing Market Growth of 5.81% by 2019 - Analysis, Technologies & Forecasts Reports 2015-2019 - Key Vendors: Roche, Bio-Rad Laboratories & Trinity Biotech
M2 - Thu Jan 21, 6:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/fqsrqq/infectious) has announced the addition of the "Infectious Disease Testing Market in the US 2015-2019" report to their offering. This market report forecasts the infectious disease testing market in the US to grow at a CAGR of 5.81% over the period 2014-2019. The report covers the current scenario and the growth prospects of the infectious disease testing market in the US for the period of 2015-2019. To calculate the market size, we consider the revenue generated from the sales of equipment and consumables from molecular diagnostics, POCT diagnostic devices, and immunodiagnostics, which are used to detect infectious diseases: Questions Answered: - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned: - Abbott Diagnostics - Alere - Beckman Coulter Diagnostics - Roche - Siemens Healthcare - Abaxis - Acon Laboratories - Avioq - BD - Bio-Rad Laboratories - Cavidi - Cepheid - Chembio Diagnostic Systems - Clarity Diagnostics - EMD Millipore - Epitope Diagnostic - Gold Standard Diagnostics - Hologic - Immunetics - InBios International - Life Technologies - Maxim Biomedical - Mindray - OraSure Technologies - Ortho Clinical Diagnostics - Quidel Corporation - Thermo Fisher Scientific - Trinity Biotech Report Structure: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Market landscape PART 06: Market segmentation by application PART 07: Geographical segmentation PART 08: Market drivers PART 09: Impact of drivers PART 10: Market challenges PART 11: Impact of drivers and challenges PART 12: Market trends PART 13: Vendor landscape PART 14: Key vendor analysis PART 15: Key recommendations for vendors/investors PART 16: Appendix For more information visit http://www.researchandmarkets.com/research/fqsrqq/infectious
LIFE: 3.37 (-0.04), ABAX: 49.48 (+0.02), CPHD: 35.97 (+0.64), TRIB: 13.02 (+0.19), HOLX: 38.96 (+0.47), OSUR: 6.76 (-0.06)
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
GlobeNewswire - Wed Jan 20, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Company's Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this capacity, through an expansion of Dr. Burger's existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune diseases and cancer. He recently initiated the Company's evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Company's Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
APTO: 2.52 (+0.02), TRIB: 13.02 (+0.19), OSUR: 6.76 (-0.06)
Trinity Biotech Shares Down 37.0% Since SmarTrend's Sell Call (TRIB)
Comtex SmarTrend(R) - Tue Jan 19, 5:04PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 36.97% as of today's recent price of $10.75.
TRIB: 13.02 (+0.19)
Global Point of Care (POC) Pregnancy and Fertility Testing Market Report 2015
M2 - Tue Jan 19, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/d22vw2/poc_pregnancy_and) has announced the addition of the "POC Pregnancy and Fertility Testing Market" report to their offering. The female reproductive system is complex both in structure and in function. From birth to senescence, the organs of the female reproductive system function in concert with each other, with the brain, and with other endocrine organs. This integrated functioning constitutes some of the most intricate and elegant processes of the human body. Because the functioning of the female reproductive system has an enormous impact on the life of the individual women, increasing importance is placed on the active involvement of women in understanding their own health care needs such as determination of pregnancy and fertility. Point of care (POC) testing, diagnostic tests performed at or near the site where a patient is located, may be performed by laboratory personnel but are often performed by non-laboratory personnel, including patients themselves (self-testing). The menu for POC testing includes pregnancy and fertility testing. Point of Care (POC) Pregnancy and Fertility Testing Market examines the testing market for these segments, including: - 2014 Pregnancy and Fertility CLIA Waivers - Global POC Pregnancy and Fertility Testing Market Analysis, 2012-2019 - POC Pregnancy and Fertility Self-Testing Market Analysis, 2014 and 2019 - POC Pregnancy and Fertility Professional Testing Market Analysis, 2014 and 2019 - Global POC Pregnancy and Fertility Testing Market Revenues and Market Share of Leading Suppliers, 2014 The professional sector is made up of tests used in hospitals, physician offices and clinics. The over-the-counter (OTC) sector for pregnancy and ovulation (LH) includes tests available in pharmacies and other retail establishments. Both market segments are expected to grow over the report's forecast period. Many companies are involved in the development and/or marketing of POC pregnancy and fertility testing products. Among the top and/or innovative competitors discussed within the Corporate Profiles are firms that maintain leading positions in the market such as: - Alere - Church & Dwight - Insight Pharmaceuticals - Meridian - Quidel Key Topics Covered: ONE: EXECUTIVE SUMMARY - Overview of POC Testing - Pregnancy and Fertility - Size of the Market - POC Professional Testing - POC Pregnancy and Fertility Self-Testing - Growth of the Market - Leading Competitors TWO: POC PREGNANCY AND FERTILITY TESTING - Products - Market Size and Growth - POC Pregnancy and Fertility Self-Testing - POC Pregnancy and Fertility Professional Testing - Competitive Analysis - Product Innovation THREE: CORPORATE PROFILES - Alere Inc - Ani Biotech Oy - Beckman Coulter, Inc - bioMerieux SA - Cen-Med Enterprises, Inc. - Church & Dwight Co., Inc - EKF Diagnostics GmbH - EKLA Corporation - Insight Pharmaceuticals LLC - Meridian BioScience, Inc - Opko Health, Inc - Polymed Therapeutics Inc. - Polymedco, Inc - Quidel Corporation - Radiometer Medical ApS - Ramco Laboratories, Inc. - Roche Diagnostics Corporation - Siemens Healthcare - Stanbio Laboratory - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/d2...gnancy_and
CHD: 98.35 (+0.11), VIVO: 19.48 (+0.12), OPK: 9.95 (unch), TRIB: 13.02 (+0.19), ALR: 37.21 (-0.29)
Hemoglobin A1c Testing Markets 2016 - The Global Prevalence of Diabetes Mellitus Continues to Increase Rapidly, with More than 366 Million Diabetics Worldwide
M2 - Wed Jan 13, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/wqvpk6/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Markets" report to their offering. Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase rapidly, with more than 366 million diabetics worldwide, hemoglobin A1c testing is now an essential assay in the diabetes testing repertoire. Its clinical utility and improvements in its accuracy and implementation of standardized protocols have translated into continued market growth. This report describes the specific market segment that encompasses hemoglobin A1c testing for diagnosing and monitoring diabetes. The study reviews all of the generally accepted clinical analytical methods that are currently in use today for measuring HbA1c levels. Moreover, it examines clinical measurement devices and reagents as utilized in hospitals, clinics, doctor's offices and at-home care locations. The report also analyzes almost all of the companies known to be marketing, manufacturing or developing hemoglobin A1c testing. Detailed tables and charts with sales forecasts and market-share data are also included. Companies Mentioned - Abbott Laboratories - A. Menarini Diagnostics - Alere, Inc. - ARKRAY USA, Inc. - Axis-Shield Plc - Bayer Healthcare Diagnostics - Beckman Coulter, Inc - Bio-Rad Laboratories, Inc. - EKF Diagnostics - Infopia Co., Ltd. - Ortho Clinical Diagnostics (part of Johnson & Johnson) - Quotient Diagnostics - Randox Laboratories - Roche Diagnostics - Siemens AG - Tosoh Bioscience, Inc. - Trinity Biotech Plc Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Overview of HbA1c Testing 5. HbA1c Testing Devices on the Market 6. Business Trends in HbA1c Testing 7. Regulatory Environment and Insurance Reimbursements 8. Company Profiles For more information visit http://www.researchandmarkets.com/research/wq...globin_a1c
JNJ: 125.15 (-0.08), ABT: 45.07 (+0.32), TRIB: 13.02 (+0.19), ALR: 37.21 (-0.29)
Trinity Biotech Has Returned 36.8% Since SmarTrend Recommendation (TRIB)
Comtex SmarTrend(R) - Tue Jan 12, 11:03AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 6 months, Trinity Biotech has returned 36.79% as of today's recent price of $10.78.
TRIB: 13.02 (+0.19)
Downtrend Call Working As Trinity Biotech Stock Falls 31.1% (TRIB)
Comtex SmarTrend(R) - Tue Jan 05, 9:15AM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 5 months, Trinity Biotech has returned 31.11% as of today's recent price of $11.75.
TRIB: 13.02 (+0.19)
Dengue Virus Pipeline Review, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/43hcsk/dengue_virus) has announced the addition of the "Dengue Virus - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dengue Virus diagnostic tests pipeline products. Key Topics Covered: - Extensive coverage of the Dengue Virus diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Dengue Virus diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Dengue Virus diagnostic tests under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Companies Mentioned: - Acobiom - Ceres Nanosciences, Inc. - Chembio Diagnostic Systems, Inc. - Corgenix Medical Corporation - Epistem Holdings Plc - FK-Biotecnologia SA - GeneFirst Ltd - InBios International, Inc. - Innova Biotechnology Co., Ltd. - InstantLabs Medical Diagnostics Corporation - Institut Pasteur - Malaysian Bio-Diagnostics Research Sdn Bhd - McGill University - Micronics, Inc. (of Sony Group) - Nanyang Technological University - National University of Singapore - Trinity Biotech Plc - Universitas Padjadjaran - University of California, Berkeley - University of Texas Medical Branch at Galveston - Vircell S.L - Whidiag SAS Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Dengue Virus - Pipeline Products under Development by Companies 5 Dengue Virus Companies and Product Overview 6 Dengue Virus- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/43...ngue_virus
TRIB: 13.02 (+0.19)
Trinity Biotech Down 28.9% Since SmarTrend Downtrend Call (TRIB)
Comtex SmarTrend(R) - Mon Dec 21, 3:58PM CST
SmarTrend identified a Downtrend for Trinity Biotech (NASDAQ:TRIB) on July 28th, 2015 at $17.06. In approximately 5 months, Trinity Biotech has returned 28.94% as of today's recent price of $12.12.
TRIB: 13.02 (+0.19)
Global In Vitro Diagnostic Instrumentation & Strategic Profiles of Leading Suppliers - Analysis, Technologies & Forecasts 2016
M2 - Mon Dec 21, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/8znjj3/2016_world_in) has announced the addition of the "2016 World In Vitro Diagnostic Instrumentation and Strategic Profiles of Leading Suppliers" report to their offering. This new report reviews operating characteristics and features of major automated and semi-automated high-, medium-, and low-volume/POC in vitro diagnostic systems within the following market segments: - Blood Typing, Grouping, and Screening - Cancer Diagnostics - Clinical Chemistry and Immunodiagnostics - Coagulation Testing - Hematology and Flow Cytometry - Microbiology - Molecular Diagnostics The report also presents strategic assessments of current and emerging suppliers of in vitro diagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. The companies analyzed in the report include: - Abbott - Affymetrix - Agilent Technologies - Alere/AdnaGen - Applied Gene Technologies - Lonza - Mackay Life Sciences - Matritech/Alere - Monogram Biosciences/LabCorp - Shimadzu - Siemens - Sienco - Sierra Molecular - Sysmex - Takara Bio - Targeted Diagnostics & Therapeutics - Tecan Group - Thermo Fisher - Tosoh - Trinity Biotech - Veridex - Vermillion - Wako - Wallac/PE - Zycare/Alere - Zyla Contains 370 pages For more information visit http://www.researchandmarkets.com/research/8z...6_world_in
A: 47.76 (-0.35), TRIB: 13.02 (+0.19)
